Eye-tracking component maker Tobii has gone public in a $46m initial public offering, roughly three years after Intel paid $21m for a 10% stake.

The cancer treatment developer raised $52.8m, floating beneath its $14 to $16 range, as existing backer Fidelity invested $8m.

The mobile game studio raised $14m from Link and Motivation and Globis in 2014 and is now looking to go public in its home country of Japan.

The gene therapy developer, backed by Roche Venture Fund, floated in the middle of its range after raising more than $80m in venture funding.

The China-based immuno-oncology company, backed by Merck & Co since 2011, floated at the top of it range and has gained since its debut yesterday.

Genome editing company Editas, backed by Alphabet and Partners Healthcare, has secured $94.4m, pricing the initial public offering at the bottom of the $16 to $18 range.

The company could secure up to $60.8m in proceeds, having previously raised equity and debt from investors such as Novartis, Sanofi and Elan Science One.

Roche-backed AveXis, the developer of a spinal muscular atrophy treatment, intends to issue 4.25 million shares priced between $19 and $21.

Pharmaceutical firm Strides Arcolab holds a 12% stake in the biosimilar developer after investing $9m in 2014.

The Belgium-based stem cell therapy developer, which is backed by investors including Gri-Cel and Novartis, has filed to go public in the US.